Aduro Biotech reports preclinical data supporting development of antibody BION-1301
Aduro Biotech announced data from preclinical studies supporting the clinical development of the company's proprietary monoclonal antibody BION-1301, a humanized anti-APRIL (A PRoliferation-Inducing Ligand) antibody for treatment of multiple myeloma. December 03, 2016